Featured Articles

Voro Therapeutics has entered into a research collaboration with Daiichi Sankyo to develop next-generation antibody-drug conjugates (ADCs) using its proprietary PrimeBody platform. The…
Read More...

Roche has announced a major expansion of its global artificial intelligence (AI) infrastructure, unveiling a large-scale “AI factory” powered by next-generation accelerated computing…
Read More...

Johnson & Johnson has received approval from the U.S. Food and Drug Administration for its TECNIS PureSee intraocular lens (IOL), a new extended depth of focus (EDOF) lens designed…
Read More...

Danish pharmaceutical company Novo Nordisk has announced a new agreement with telehealth platform Hims & Hers Health aimed at expanding patient access to its FDA-approved…
Read More...

GSK plc has entered into a licensing agreement with Alfasigma S.p.A. granting the Italian pharmaceutical company exclusive global rights to develop, manufacture, and commercialize…
Read More...

Pharmaceutical company GSK plc has entered into a licensing agreement with Italian drugmaker Alfasigma S.p.A. granting the latter worldwide exclusive rights to develop, manufacture and…
Read More...

Innovative biotech firm Antengene Corporation Limited has entered into a major global licensing agreement with biopharmaceutical company UCB to advance the development of ATG-201, a…
Read More...

The Ministry of Health, Labour and Welfare has granted orphan drug designation to rilzabrutinib, an investigational oral therapy, for the treatment of IgG4-related disease (IgG4-RD).…
Read More...

Pharmaceutical giant Novo Nordisk has announced a €432 million investment to expand its manufacturing facility in Athlone, Ireland, a move aimed at increasing production capacity for…
Read More...

Novo Nordisk and Vivtex Corporation have announced a strategic partnership to develop next-generation oral biologic medicines targeting obesity, diabetes and related metabolic…
Read More...

IQVIA Holdings Inc. has entered into an agreement to acquire certain drug discovery services assets from Charles River Laboratories, a move designed to expand its early-stage research…
Read More...

GSK plc has agreed to acquire 35Pharma Inc., a privately held Canadian biopharmaceutical company focused on protein-based therapeutics. The deal brings into GSK’s pipeline HS235, an…
Read More...

Gilead Sciences, Inc. has entered into a definitive agreement to acquire Arcellx in a transaction valued at approximately $7.8 billion, strengthening its oncology and cell therapy…
Read More...

AbbVie has unveiled plans to invest $380 million to construct two new active pharmaceutical ingredient (API) manufacturing facilities at its North Chicago, Illinois campus, expanding…
Read More...

AbbVie has announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for the combination of VENCLEXTA® (venetoclax) and acalabrutinib…
Read More...

Merck & Co., Inc., known as MSD outside the United States and Canada, has entered into a major research and development agreement with Mayo Clinic to apply artificial intelligence…
Read More...

Novartis has announced positive topline results from its pivotal Phase III RemIND trial evaluating oral remibrutinib in patients with chronic inducible urticaria (CIndU), a condition…
Read More...

Boehringer Ingelheim India Private Limited has signed a Memorandum of Understanding (MoU) with National Institute of Pharmaceutical Education and Research, Raebareli (NIPER Raebareli),…
Read More...

Johnson & Johnson has announced plans to invest more than $1 billion in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania, further…
Read More...

Biotechnology company Amgen has received authorization from the European Commission for UPLIZNA as an add-on therapy for adults with generalized myasthenia gravis (gMG) who test…
Read More...